구조모아 (StructureMoa)항암 chemical structure spider web
방문Auto-discovered from ClinicalTrials.gov (131 linked trials). Disease-specific study endpoint: 64. The purpose of this study is to assess the antitumor efficacy of single-agent brent….
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Hodgkin Disease
Hodgkin's Disease
Approved
brentuximab-vedotin
2026-09-10
Data Confidence · High
Development Signal · Established
ADCs) increased the antitumor effect of mAbs
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
구조화 데이터
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
resistance mechanisms and improving outcomes in relapsed or refractory disease
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
Hodgkin Disease · biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell accessibility to tumor cells, leading to improved T-cell activation
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
구조화 데이터
xenograft (PDX) model
mouse
pharmacodynamic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Auto-discovered from ClinicalTrials.gov (131 linked trials). Disease-specific study endpoint: 64. The purpose of this study is to assess the antitumor efficacy of single-agent brent….
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Hodgkin Disease
Hodgkin's Disease
Approved
brentuximab-vedotin
2026-09-10
Data Confidence · High
Development Signal · Established
ADCs) increased the antitumor effect of mAbs
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
구조화 데이터
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
resistance mechanisms and improving outcomes in relapsed or refractory disease
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
Hodgkin Disease · biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell accessibility to tumor cells, leading to improved T-cell activation
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
구조화 데이터
xenograft (PDX) model
mouse
pharmacodynamic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.